With the FDA approval of plasminogen, human-tvmh (Ryplazim, Kedrion Biopharma) there is an effective treatment for plasminogen deficiency type 1 (PLGD-1), a rare systemic disorder characterized primarily by ligneous conjunctivitis. Here, test your knowledge of the PLGD-1 diagnosis.
